The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
Sara M. Tolaney
Research Funding - Genentech
Dan G. Duda
No relevant relationships to disclose
Yves Boucher
No relevant relationships to disclose
Shom Goel
No relevant relationships to disclose
John Martin
No relevant relationships to disclose
Marek Ancukiewicz
No relevant relationships to disclose
Hannah Potler
No relevant relationships to disclose
Jaoa Incio
No relevant relationships to disclose
Jennifer A. Ligibel
No relevant relationships to disclose
Steven J. Isakoff
Research Funding - Genentech
Dai Fukumura
No relevant relationships to disclose
Eric P. Winer
Research Funding - Genentech
Ian E. Krop
Research Funding - Genentech
Rakesh K. Jain
Research Funding - MedImmune; Roche